Carmustine and lomustine nitrosoureas disintegrate to produce reactive intermediates that serve as classic alkylating agents in the body. is given intravenously, while administered orally. They both act anti-cancer drugs; could be used treat brain tumors. To know correct synthesis reactivity of molecules, structural analysis very important. This research indicates characterization carmustine dr...

Abstract Given the rarity of adult medulloblastoma, optimal chemotherapy strategy is unknown and its management thought to vary from institution institution. Guidelines often omit suggestions for specific regimens, reflecting lack high-quality evidence in this population. We sought understand Canadian medulloblastoma practice patterns, hoping inform future quality metrics guidelines. METHODS: I...

Abstract Background Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG). However, 1 year of PCV is associated with significant toxicities. In the pivotal RTOG 9802 randomised control trial, approximately half patients discontinued treatment after 6 months. As on clinical trials may be fitter, we aimed t...

Abstract AIMS Most patients with glioblastoma recur despite surgery and post-operative chemoradiation. The optimal second line chemotherapy regime is not known. aim of this study was to evaluate PCV given as treatment for glioblastoma. METHOD Data collected all treated between 2009 2021 at the Norfolk Norwich University Hospital. All underwent surgical resection either complete or incomplete fo...

1. Rana SB, Pokharel S. A dosimetric study of volumetric modulated arc therapy planning techniques for treatment of low-risk prostate cancer in patients with bilateral hip prostheses. South Asian J Cancer 2014;3:18-21. 2. Rana S, Cheng C, Zheng Y, Hsi W, Zeidan O, Schreuder N, et al. Dosimetric study of uniform scanning proton therapy planning for prostate cancer patients with a metal hip prost...

We present a case report of 56-year-old woman who was diagnosed with biopsy-proven left thalamic glioblastoma multiforme (GBM). She treated standard concurrent chemotherapy and radiation, as well 2-year period adjuvant temozolomide. relapsed 2 ½ years after starting her initial therapy bevacizumab lomustine, but she relapsed. then placed on phase 1/2 clinical trial that included KHK2455 mogamul...